CCChudi Chang

Chudi Chang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chudi Chang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Dong

    Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China

    1 shared publication
  • Jiawei Cui

    Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China

    1 shared publication
  • Jie Li

    Department of Infectious Diseases Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing Jiangsu China

    1 shared publication
  • Jinhua Shao

    Wuxi Hisky Medical Technologies Co., Ltd, Wuxi, China

    1 shared publication
  • Liang Qiao

    Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney at Westmead Hospital, Westmead, NSW, 2145, Australia

    1 shared publication
  • Mengmeng Hou

    Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China

    1 shared publication

Latest Publications

  • Open Access

    The relationship between MAFLD and CVD in a health check-up Chinese population: a prospective cohort study

    by Yao Dou, Jiawei Cui, Qi Gu, Xiwei Yuan, Mengmeng Hou, Wenjing Ni, Chen Dong, Chudi Chang, Jinhua Shao, Qiuling Wang, et al.

    Background: Cardiovascular disease (CVD) has emerged as the most significant complication and leading cause of death among metabolic-associated fatty liver disease (MAFLD). Objectives: This study aims to investigate the CVD risk among MAFLD subgroups. Design: Data of participants from June 2017 to January 2023 in the Physical Examination Center of the Third Hospital of Hebei Medical University were collected. MAFLD were divided into four subgroups: metabolic healthy lean/normal weight MAFLD (MHL), metabolic healthy overweight/obese MAFLD (MHO), metabolic dysfunctional lean/normal weight MAFLD (MDL), and metabolic dysfunctional overweight/obese MAFLD (MDO). Methods: The risk assessment for atherosclerotic CVD was performed based on the flowchart for primary prevention risk assessment in Chinese adults. Results: The proportions of MHL, MHO, MDL, and MDO were 0.77% ( n = 185), 10.05% ( n = 2406), 1.29% ( n = 310), and 16.86% ( n = 4038), respectively. After adjustment for gender, age, smoking history, drinking history, and significant liver fibrosis, the subgroup of MAFLD was still an independent risk factor for high adverse cardiovascular events (HACE). Compared with the MHL, the MDL had the highest risk, followed by MDO (all p < 0.05), and there was no significant difference between MHO and MHL. We performed regression analysis according to age (65 years) and gender (male or female), respectively, and the results were similar to those of the total population. Conclusion: MAFLD is associated with a higher risk of CVD, especially in MDO. Classification of MAFLD based on body mass index and metabolic status helps in risk stratification, which will mitigate or prevent the development of CVD.